These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7871409)

  • 21. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 22. How FDA approves biotechnology drugs.
    Manuel SM; Piascik P
    Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 24. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 25. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
    Peck CC; Rubin DB; Sheiner LB
    Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
    [No Abstract]   [Full Text] [Related]  

  • 26. Bill to boost medical research funding and speed drug approval passes US house.
    McCarthy M
    BMJ; 2016 Dec; 355():i6498. PubMed ID: 27908875
    [No Abstract]   [Full Text] [Related]  

  • 27. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The special treatment.
    Osborne R
    Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
    [No Abstract]   [Full Text] [Related]  

  • 29. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C; Rusch LM
    J Clin Pharmacol; 2016 Mar; 56(3):257-9. PubMed ID: 26211513
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment research at the millennium: from efficacy to effectiveness.
    Lebowitz BD; Rudorfer MV
    J Clin Psychopharmacol; 1998 Feb; 18(1):1. PubMed ID: 9472835
    [No Abstract]   [Full Text] [Related]  

  • 32. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
    Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
    Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
    [No Abstract]   [Full Text] [Related]  

  • 33. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.
    Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ
    Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875
    [No Abstract]   [Full Text] [Related]  

  • 34. US FDA feels the heat from Congressional hearings.
    Loewenberg S
    Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
    [No Abstract]   [Full Text] [Related]  

  • 35. Disease models.
    Gobburu J
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
    [No Abstract]   [Full Text] [Related]  

  • 36. Transforming the Activation of Clinical Trials.
    Watters JT; Pitzen JH; Sanders LJ; Bruce VNM; Cornell AR; Cseko GC; Grace JS; Kwon PS; Kukla AK; Lee MS; Monosmith MD; Myren JD; Kottschade RS; Shaft MN; Weis JJA; Welter JC; Bharucha AE
    Clin Pharmacol Ther; 2018 Jan; 103(1):43-46. PubMed ID: 29105757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA approval signals more 'homework' on the horizon in trials.
    Waters H
    Nat Med; 2011 Jul; 17(7):754. PubMed ID: 21738130
    [No Abstract]   [Full Text] [Related]  

  • 38. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 39. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 40. Who pays what in drug development.
    Love J
    Nature; 1999 Jan; 397(6716):202. PubMed ID: 9930689
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.